ReviewDiscover oncology2026
Nervous and immune system crosstalk shapes cancer progression and treatment response.
Review in Discover oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- The microbiome as a systems-level regulator of immune, metabolic, neural, and endocrine signaling in cancer.Frontiers in immunology · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The nervous and immune systems, though traditionally studied as separate entities, are now recognized as deeply interconnected networks that jointly regulate tumor initiation, progression, and therapeutic response. Neural elements extend into the tumor microenvironment where they interact with immune cells, shaping processes such as proliferation, invasion, and metastasis. Through neurotransmitters, neuropeptides, and bidirectional signaling with the brain, nerves influence leukocyte recruitment, functional activity, and immune tone. Stress, circadian disruption, and gut–brain interactions further modulate antitumor immunity, underscoring the complexity of this axis. Evidence indicates that neuronal signaling contributes not only to cancer-related symptoms, including pain, but also to treatment outcomes in chemotherapy, radiotherapy, and immunotherapy. Neural markers may serve as prognostic tools, while targeted modulation of neural transmission could enhance antitumor responses. However, the field faces significant challenges, including cellular diversity, spatiotemporal complexity, and limitations of animal models. Advances in molecular biology, bioinformatics, and interdisciplinary collaboration are essential to unravel these mechanisms. Exploring the neuro-immune-cancer axis holds promise for novel therapeutic strategies that integrate neuroscience, immunology, and oncology,aiming to improve both quality of life and survival in patients with cancer.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.